Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 9/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21237196 | 1.00 | CREBBP (0.51) | CREBBPMAP4K4NOTUMPDE10ARXFP1 | |
| SCHEMBL21237331 | 0.88 | CREBBP (0.40) | CREBBPNOTUM | |
| SCHEMBL19663332 | 0.86 | CREBBP (0.55) | CREBBPMAP4K4NOTUMPDE10ARXFP1 | |
| SCHEMBL21237392 | 0.86 | CREBBP (0.51) | CREBBPNOTUMPDE10ACYP46A1 | |
| SCHEMBL21237249 | 0.82 | HRH4 (0.49) | — | |
| SCHEMBL21237243 | 0.80 | CREBBP (0.43) | CREBBPPDE10ASYKBRD4KMT2A | |
| SCHEMBL21237241 | 0.80 | CREBBP (0.43) | CREBBPPDE10A | |
| SCHEMBL21237247 | 0.80 | CREBBP (0.43) | CREBBPPDE10ASYKBRD4KMT2A | |
| SCHEMBL21237184 | 0.78 | CREBBP (0.46) | CREBBPPDE10A | |
| SCHEMBL21237185 | 0.78 | CREBBP (0.46) | CREBBPPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | CREBBP 3/4885MAP4K4 1377/4885NOTUM 3611/4885 |
| US-20190241558-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | CREBBP 3/4885MAP4K4 1377/4885NOTUM 3611/4885 |
| US-20220127265-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, CREBBP | CREBBP 3/4885MAP4K4 1377/4885NOTUM 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.